Related Experiment Video
Updated: Mar 3, 2026
Laparoscopic S7 Hepatectomy with Positive Fluorescence Staining
Published on: May 9, 2025
Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient
C Taibi1, M Tempestilli1, A D'Avolio2
1National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S., Rome, Italy.
What Is Known And Objective:
The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients.
Case Description:
We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment.
What Is New And Conclusion:
This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.
